0000950170-24-051244.txt : 20240501
0000950170-24-051244.hdr.sgml : 20240501
20240501160511
ACCESSION NUMBER: 0000950170-24-051244
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240429
FILED AS OF DATE: 20240501
DATE AS OF CHANGE: 20240501
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Okazaki Jason A
CENTRAL INDEX KEY: 0001807214
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35005
FILM NUMBER: 24902909
MAIL ADDRESS:
STREET 1: C/O ASSEMBLY BIOSCIENCES, INC.
STREET 2: 331 OYSTER POINT BLVD, FOURTH FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ASSEMBLY BIOSCIENCES, INC.
CENTRAL INDEX KEY: 0001426800
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: TWO TOWER PLACE
STREET 2: 7TH FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (833) 409-4583
MAIL ADDRESS:
STREET 1: TWO TOWER PLACE
STREET 2: 7TH FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: VENTRUS BIOSCIENCES INC
DATE OF NAME CHANGE: 20080211
4
1
ownership.xml
4
X0508
4
2024-04-29
0001426800
ASSEMBLY BIOSCIENCES, INC.
ASMB
0001807214
Okazaki Jason A
C/O ASSEMBLY BIOSCIENCES, INC.
TWO TOWER PLACE, 7TH FLOOR
SOUTH SAN FRANCISCO
CA
94080
true
true
false
false
CEO and President
false
Common Stock
2024-04-29
4
A
false
4166
0
A
17992
D
Common Stock
2024-04-30
4
S
false
1569
12.7068
D
16423
D
Represents shares of common stock issuable under a performance-based restricted stock unit award dated August 1, 2022. On April 29, 2024, a performance-based vesting condition was achieved.
The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.3851 to $12.8847, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.
/s/ John O. Gunderson, as Attorney-in-Fact
2024-05-01